Increased α-synuclein phosphorylation and nitration in the aging primate substantia nigra

AL McCormack¹, SK Mak¹ and DA Di Monte*¹

Post-translational modifications of α-synuclein occur in the brain of patients affected by Parkinson’s disease and other α-synucleinopathies, as indicated by the accumulation of Lewy inclusions containing phosphorylated (at serine 129) and nitrated α-synuclein. Here we found that phospho-Ser 129 and nitrated α-synuclein are also formed within dopaminergic neurons of the monkey substantia nigra as a result of normal aging. Dopaminergic cell bodies immunoreactive for phospho-Ser 129 and nitrated α-synuclein were rarely seen in adult mature animals but became significantly more frequent in the substantia nigra of old primates. Dual labeling with antibodies against phospho-Ser 129 and nitrated α-synuclein revealed only limited colocalization and mostly distinct sub-populations of dopaminergic neurons. Age-related elevations of modified protein paralleled an increase in the number of neurons immunoreactive for unmodified α-synuclein, supporting a relationship between higher levels of normal protein and enhanced phosphorylation/nitration. Other mechanisms were also identified that likely contribute to α-synuclein modifications. In particular, increased expression of Polo-like kinase 2 within neurons of older animals could contribute to phospho-Ser 129 α-synuclein production. Data also indicate that a pro-oxidant environment characterizes older neurons and favors α-synuclein nitration. Aging is an unequivocal risk factor for human α-synucleinopathies. These findings are consistent with a mechanistic link between aging, α-synuclein abnormalities and enhanced vulnerability to neurodegenerative processes.

Cell Death and Disease (2012) 3, e315; doi:10.1038/cddis.2012.50; published online 31 May 2012
Subject Category: Neuroscience

Pathological changes of α-synuclein are hallmarks of idiopathic Parkinson’s disease (PD) and other age-related neurodegenerative disorders such as dementia with Lewy bodies and multiple system atrophy.¹ ² Intraneuronal accumulation of insoluble α-synuclein, as reflected by the formation Lewy bodies and Lewy neurites, is typically observed in postmortem brains of all PD patients, and the spreading of these inclusions throughout the brainstem, meso- and neocortex underlies a pathological staging of PD progression that was first proposed by Braak et al.³ Post-translational α-synuclein modifications are also a feature of PD: specific kinases catalyze α-synuclein phosphorylation (particularly at serine 129), and oxidative/nitrative reactions lead to the accumulation of nitrated α-synuclein within Lewy inclusions.⁴ ⁵ ⁶ Interestingly, protein deposition, phosphorylation and nitration may be interrelated, as suggested by findings showing that α-synuclein’s tendency to aggregate is affected by its post-translational modifications.⁷ ⁸ ⁹ ¹⁰ Furthermore, because modified forms of α-synuclein possess toxic properties, accumulation of insoluble, phosphorylated and/or nitrated protein could be a key event linking α-synuclein to neuronal dysfunction and, ultimately, neuronal demise in the pathogenesis of human α-synucleinopathies.⁹ ¹⁰ ¹¹ ¹²

Aging is an unequivocal PD risk factor, although the precise mechanisms by which neuronal susceptibility to degenerative processes is augmented by age remain unclear.¹² ¹³ Interestingly, recent work showing increased levels of α-synuclein protein in both human and non-human primate substantia nigra supports a relationship between aging and α-synuclein. Using a semiquantitative immunoblot analysis, Li et al.¹⁴ found a 100% increase in nigral α-synuclein in individuals > 80 years of age as compared with subjects < 60 years old; in contrast, α-synuclein levels were unaffected by age in the frontal cortex and caudate nucleus. Subsequent studies also reported an increase in the number, optical density and fluorescence intensity of α-synuclein-immunoreactive neurons as a function of age in the substantia nigra but not the ventral tegmental area of humans and rhesus monkeys.¹⁴ ¹⁵ Finally, experimental evidence indicates that age-related α-synuclein changes are rather unique to primates as levels of this protein actually decline in the mouse substantia nigra.¹⁶ The primate substantia nigra is highly vulnerable to both α-synuclein pathology and neurodegeneration, raising the intriguing possibility that this enhanced susceptibility is due, at least in part, to age-related α-synuclein elevation.

Elevated α-synuclein could itself promote pathological modifications of the protein, underscoring the relevance of studies on the effects of aging on α-synuclein aggregation, phosphorylation and nitration. Two previous investigations reported lack of α-synuclein deposition in the substantia nigra of young, middle-aged and old humans and monkeys.¹⁴ ¹⁵

¹German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
²Corresponding author: DA Di Monte, German Center for Neurodegenerative Diseases (DZNE), Ludwig-Erhard-Allee 2, Bonn 53175, Germany, Tel: +49 228 43308650; Fax: +49 228 43308509; E-mail: donato.dimonte@dzne.de
Keywords: monkey; nitration; Parkinson; phosphorylation; Polo-like kinase; synuclein
Abbreviations: CMA, chaperone-mediated autophagy; PBS, phosphate-buffered saline; PD, Parkinson’s disease; PLK, Polo-like kinase
Received 22.12.11; revised 02.4.12; accepted 04.4.12; Edited by A Verkhratsky
No study to date, however, has assessed whether protein phosphorylation and nitration are affected by age and vary in parallel with changes in soluble and/or insoluble α-synuclein. In the present report, the number of neuronal cell bodies immunoreactive for normal, phospho-Ser 129 and nitrated α-synuclein was compared in the substantia nigra of young adult versus old squirrel monkeys. The focus on neuronal cell bodies is justified by the consideration that they are normally devoid of detectable immunoreactivity for nitrated or phosphorylated α-synuclein.4,6 Data indicate an age-related increase in both normal and modified protein in the absence of overt α-synuclein aggregation. Results are also consistent with the interpretation that besides the increase in normal α-synuclein levels enhanced kinase expression and pro-oxidant/nitrative conditions contribute to the production of phospho-Ser 129 and nitrated α-synuclein, respectively, in older nigral neurons.

Results

Age-related α-synuclein accumulation within dopaminergic cell bodies. Aging was accompanied by an increase in nigral cell bodies immunoreactive for α-synuclein. Quantification of this effect revealed a significant difference between mature ( <10 years of age) and old ( >16 years old) monkeys. The total number of α-synuclein-immunoreactive cells was 60% greater in the latter than the former age group, and α-synuclein-positive cell bodies constituted 17% and 27% of the total count of nigral dopaminergic neurons in mature and old squirrel monkeys, respectively (Table 1). Interestingly, α-synuclein immunoreactivity was consistently associated with neuromelanin-containing neurons and, in fact, the number of unpigmented cell bodies expressing detectable levels of α-synuclein was negligible (<1% of the total count of dopaminergic cells) in either mature or old animals (Table 1).

Age-related α-synuclein phosphorylation. Phosphorylation at Ser129 has been reported to be the predominant modification of α-synuclein in Lewy bodies.17 An antibody that specifically recognizes phospho-Ser 129 α-synuclein4 was used to determine whether neuronal cell bodies in the primate substantia nigra contain this modified form of the protein and whether α-synuclein phosphorylation is enhanced by aging. Phospho-Ser 129 α-synuclein-immunoreactive neurons were rarely detected in midbrain sections from mature monkeys but became a more frequent feature of nigral specimens from old animals (Figures 1a and b). In the former, only ~1% of dopaminergic neurons displayed detectable immunoreactivity for phospho-Ser 129 α-synuclein. In old animals, counts of these cells revealed an eightfold increase (Figure 1c), and nigral neurons immunoreactive for phospho-Ser 129 α-synuclein represented 7.3% of the total number of dopaminergic cells. To ensure specificity of these effects, tissue sections were stained with a second antiphospho-Ser 129 α-synuclein antibody.17 A similar pattern of immunoreactivity and age-related changes was observed (data not shown).

In a second set of experiments, midbrain sections were double stained with antibodies against phospho-Ser 129 α-synuclein and unmodified α-synuclein. Fluorescence microscopy on sections stained for phospho-Ser 129 α-synuclein confirmed the formation of phosphorylated protein within dopaminergic neurons. Earlier investigations in vitro (e.g., HeLa cells) have reported a nuclear enrichment of phospho-Ser 129 α-synuclein, and data in mice (e.g., transgenic animals overexpressing α-synuclein) also showed nuclear anti-phospho-Ser 129 α-synuclein immunostaining, particularly in cortical brain regions.5,18 Our present observations were consistent with the presence of both cytosolic and nuclear phospho-Ser 129 α-synuclein in the monkey substantia nigra (Figure 1d). Colocalization of total and phospho-Ser 129 α-synuclein immunoreactivities was also assessed. In all instances, cell bodies stained for phospho-Ser 129 α-synuclein were also immunoreactive for unmodified α-synuclein, consistent with the interpretation that immunoreactivity with the former antibody indeed detected phosphorylated α-synuclein. Approximately 5% of neuronal cell bodies immunoreactive for total (i.e., unmodified) α-synuclein also contained phosphorylated protein in mature monkeys; this percentage dramatically increased in old animals in which immunoreactivity for phospho-Ser 129 α-synuclein characterized 25% of nigral neurons expressing normal α-synuclein (Figures 1d–g).

Members of the Polo-like kinase (PLK) protein family and, in particular, PLK2 have an important role in α-synuclein phosphorylation at Ser129.5,19,20 Using immunohistochemistry to identify and count PLK2-expressing neurons, we found that the number of cells displaying robust staining was >3-fold greater in the substantia nigra of old as compared with mature monkeys (Figures 2a–c). As these neurons also contained neuromelanin, data are consistent with a marked age-related enhancement of PLK2 levels within dopaminergic cell bodies. Dual staining and fluorescence microscopy

Table 1

| Age (years) | DAergic cells |  α-Synuclein-i.r. cells |
|-------------|---------------|------------------------|
|              | Total          | NM containing | No NM | Total          | NM containing | No NM |
| <10 (n = 4) | 213 ± 7.0      | 164 ± 10 (77%)  | 49 ± 12 (23%) | 36.5 ± 1.2     | 17.1 (17%)  | 0.8 ± 0.3 (0.4%) |
| >16 (n = 3) | 218 ± 3.0      | 206 ± 1.0 (95%) | 12 ± 2.0 (5%)  | 58 ± 4.6       | 26.6%*       | 0.7 ± 0.3 (0.3%) |

Abbreviations: DAergic, dopaminergic; i.r., immunoreactive; NM, neuromelanin

For each animal, counts were made in two midbrain sections at the level of the third nerve, and values from the two sections were averaged. The total number of DAergic neurons was the sum of NM-containing cells plus tyrosine hydroxylase-i.r. neurons devoid of NM. α-Synuclein immunoreactivity was detected within pigmented neuronal cell bodies, i.e., NM-containing cells and, rarely, within neurons devoid of NM. Results are the means ± S.E.M.; *P < 0.01 versus the corresponding value in younger animals. Values in parenthesis show the percent of the total number of dopaminergic cells.
allowed us to evaluate whether expression of PLK2 was associated with α-synuclein phosphorylation within the same neurons. Data revealed a substantial colocalization of phospho-Ser129 α-synuclein and PLK2, with >80% of phosphorylated α-synuclein-immunoreactive neurons also staining for PLK2 in the substantia nigra of either mature or old animals (Figures 2d–g).

α-Synuclein nitration in aging nigral neurons. Antibodies that react with nitrated tyrosine residues of α-synuclein label Lewy inclusions in PD and other human α-synucleinopathies.6 Midbrain sections from mature and old monkeys were therefore stained with an anti-nitrated α-synuclein antibody to detect potential age-related modifications. Similar to the results with phosphorylated protein, immunoreactivity for nitrated α-synuclein was rarely detected within nigral neurons of mature animals; indeed, only 0.6% of dopaminergic neurons displayed detectable immunoreactivity for nitrated α-synuclein in this age group. In contrast, the anti-nitrated α-synuclein antibody robustly stained neuromelanin-containing

Figure 1 The number of dopaminergic cell bodies immunoreactive for phosphorylated α-synuclein is increased in the substantia nigra of old monkeys. Four mature and three old squirrel monkeys were used for these experiments. Representative midbrain sections from a mature (a) and an old (b) animal were immunostained for phospho-Ser 129 α-synuclein (brown) and counterstained with cresyl violet (purple). (c) The number of pigmented nigral neurons immunoreactive for phospho-Ser 129 α-synuclein was counted in mature (<10 years of age) and old (>16 years old) monkeys. Data are the means ± S.E.M.; *P < 0.001 versus the mature age group. A representative midbrain section from an aged monkey was dual labeled for phospho-Ser 129 α-synuclein (d) and (unmodified) α-synuclein (e). The merged image (f) shows colocalization within a nigral neuron. Arrows indicate nuclear immunoreactivity. (g) In double-labeled sections, the number of neurons immunoreactive for phospho-Ser 129 α-synuclein was counted and expressed as percent of the total number of neurons stained for (unmodified) α-synuclein. Results are the means ± S.E.M.; *P < 0.001 versus the mature age group. Scale bar for panels a and b (in panel b) = 10 μm. Scale bar for panels d–f (in panel f) = 5 μm

Figure 2 PLK2 immunoreactivity is enhanced in the substantia nigra of old (n = 3) as compared with mature (n = 4) squirrel monkeys. Representative midbrain sections from a mature (a) and an old (b) animal were immunostained for PLK2 (brown) and counterstained with cresyl violet (purple). (c) pigmented PLK2-immunoreactive neurons were counted in the substantia nigra of mature (<10 years of age) and old (>16 years old) monkeys. Data are the means ± S.E.M.; *P < 0.001 versus the mature age group. A representative midbrain section from an old animal was dual labeled for phospho-Ser 129 α-synuclein (d) and PLK2 (e). The merged image (f) shows colabeling within a nigral neuron. (g) In double-labeled sections, the number of neurons immunoreactive for PLK2 was counted and expressed as percent of the total number of neurons stained for phospho-Ser 129 α-synuclein. Results are the means ± S.E.M. Scale bar for panels a and b (in panel b) = 10 μm. Scale bar for panels d–f (in panel f) = 5 μm
cell bodies scattered throughout the substantia nigra of old monkeys (Figures 3a and b). Cell counts using bright-field microscopy confirmed that the number of neurons containing nitrated α-synuclein was nine times higher in the older age group (Figure 3c). In these animals, the count of neurons positive for nitrated α-synuclein was 5.2% of the total number of nigral dopaminergic neurons (data not shown).

To determine what percentage of cell bodies immunoreactive for unmodified α-synuclein contained detectable levels of nitrated protein, neuronal counts were performed using fluorescence microscopy on sections double labeled for total and nitrated α-synuclein: data indicate that the count of cell bodies immunoreactive for nitrated α-synuclein, expressed as a percentage of the total number of α-synuclein-positive neurons, increased from 6.3% in mature monkeys to 19.4% in old animals (Figures 3d–g).

The formation of nitrated α-synuclein is the result of nitrative reactions that could be promoted within a pro-oxidant environment. The presence of such an environment within aging dopaminergic neurons was supported by experiments in which midbrain monkey tissues were immunostained with antibodies against 4-hydroxy-2-nonenal, a product of lipid peroxidation, or 3-nitrotyrosine, a marker of protein oxidation/nitration. In both instances, the number of immunoreactive nigral neurons was significantly increased with age. The percentage of neuromelanin-containing cells that were also immunoreactive for 4-hydroxy-2-nonenal was 25% and 70% in mature and old animals, respectively (Figures 4a–c); staining with anti-3-nitrotyrosine characterized 20 and 60% of nigral dopaminergic neurons in the two age groups (Figures 4d–f).

**Colocalization of phosphorylated and nitrated α-synuclein.** The formation of phosphorylated and nitrated α-synuclein and their parallel accumulation in the aging substantia nigra raise the question of whether these modified forms of the protein colocalize within the same dopaminergic neurons. To address this question, midbrain sections from mature and old monkeys were double immunostained with specific antibodies against phospho-Ser 129 and nitrated α-synuclein. Neurons characterized by single or double staining were observed throughout the nigral tissues of monkeys from the two age groups (Figures 5a–i). These single- or double-labeled cells were counted separately; then, the number of neurons immunoreactive for (i) phospho-Ser 129 α-synuclein only, (ii) nitrated α-synuclein only, or (iii) both phospho-Ser 129 and nitrated α-synuclein were expressed as percent of the total count (single + double stained) of immunoreactive cells. Results revealed that 30–40% of cells were single labeled for phospho-Ser 129 α-synuclein, whereas another 30–40% of neurons were stained with the anti-nitrated α-synuclein antibody (Figure 5j). Only the remaining 20–30% of cell bodies displayed immunoreactivity for both forms of modified α-synuclein, indicating that protein phosphorylation and nitration did not necessarily occur within the same population of nigral neurons. This percentage of single- and double-stained cells was not significantly different in tissues from either mature or old monkeys (Figure 5j). Thus, although the number of neurons immunoreactive for phospho-Ser 129 or nitrated α-synuclein augments with age (Figures 1 and 3), the proportion of cells in which these modified forms of the protein colocalize remains relatively constant (Figure 5j).

**Lack of α-synuclein aggregation.** In tissues immunostained for α-synuclein, immunoreactivity labeled the neuropil as well as a few dopaminergic (neuromelanin-containing) neuronal cell bodies (Figures 6a and b). To determine if
age-related changes in the number of cell bodies stained for
normal, phosphorylated and nitrated \( \alpha \)-synuclein was accom-
panied by formation of insoluble protein, midbrain sections
were incubated with proteinase K before staining with the
anti-\( \alpha \)-synuclein antibody. Immunoreactivity was completely
eliminated by proteinase K pre-treatment in samples from
either mature or old monkeys, indicating a lack of age-related
accumulation of insoluble/aggregated (proteinase K resistant)
\( \alpha \)-synuclein (Figures 6c and d).

**Discussion**

The purpose of this study was to investigate age-related
modifications of \( \alpha \)-synuclein that specifically occur within
dopaminergic cell bodies in the primate substantia nigra.
Biochemical assays (e.g., western blot analysis) performed
on tissue homogenates would have not been suitable to
detect changes within distinct neuronal populations. There-
fore, the effects of aging on nigral dopaminergic neurons were
assessed after immunostaining monkey midbrain sections
with specific antibodies against unmodified, phosphorylated
or nitrated \( \alpha \)-synuclein. Phosphorylation and nitration generate
pathological forms of \( \alpha \)-synuclein observed in the brain of PD patients.5,6 A significant outcome of this study is the
demonstration that phosphorylated and nitrated \( \alpha \)-synuclein also accumulate within neuronal cell bodies in the primate
substantia nigra as a consequence of normal aging.

In agreement with earlier investigations,14,15 we found
a significant increase in the number of dopaminergic cell
bodies immunoreactive for unmodified \( \alpha \)-synuclein in the
substantia nigra of old as compared with adult mature
monkeys. Previous work has also shown that older neurons
are characterized by enhanced immunoreactivity for unmodi-
fied \( \alpha \)-synuclein, consistent with an increase in intraneuronal
protein concentration.14 Post-translational modifications of
\( \alpha \)-synuclein as a function of aging, which were revealed in
the present study, were primarily reflected by changes in the
number of immunoreactive neurons. Indeed, dopaminergic
cell bodies positive for phospho-Ser 129 or nitrated
\( \alpha \)-synuclein were rarely seen in adult monkeys; in contrast,
a sizable sub-population of cells immunoreactive for phos-
phorylated and/or nitrated \( \alpha \)-synuclein became evident in
old animals. In the latter, ~30% of all dopaminergic
(neuromelanin-containing) neurons stained positive for
unmodified \( \alpha \)-synuclein; 25% and 20% of these \( \alpha \)-synuclein-
positive cells were co-immunoreactive for phospho-Ser
129 and nitrated \( \alpha \)-synuclein, respectively.

Results also provide important clues on the mechanisms
leading to \( \alpha \)-synuclein phosphorylation and nitration. As
already mentioned, both the current and earlier studies have
shown elevated \( \alpha \)-synuclein in the substantia nigra of humans and
non-human primates as a function of age.13–15 It is quite
conceivable therefore that changes in \( \alpha \)-synuclein expression
and post-translational modifications of the protein are related
events, with higher \( \alpha \)-synuclein resulting in more pronounced
phosphorylation and/or nitration. The reasons for marked
\( \alpha \)-synuclein elevation within older dopaminergic neurons
remain unclear. An intriguing possibility, however, concerns
the role of age-related changes in protein degradation
pathways and, in particular, the lysosomal clearance system.
Strong experimental evidence indicates that soluble mono-
meric \( \alpha \)-synuclein is a substrate for chaperone-mediated
autophagy (CMA) and that CMA activity declines as a result
of aging as well as in some age-related diseases, including
PD.21,22 It is also noteworthy that phosphorylated and nitrated
\( \alpha \)-synuclein are less susceptible to CMA degradation than
the unmodified protein,23 a feature that could contribute to
their intraneuronal accumulation.

**Figure 4** Immunolabeling for markers of oxidative stress is enhanced within older nigral neurons. Four mature and three old squirrel monkeys were used for these experiments. Representative midbrain sections from a mature (a and d) and an old (b and e) monkey were immunostained for either 4-hydroxy-2-nonenal (a and b) or 3-nitrotyrosine (d and e; brown) and counterstained with cresyl violet (purple). Pigmented cell bodies with robust immunoreactivity for these markers of oxidative stress (b and e) are more typically seen in the substantia nigra of old monkeys. (c and f) The number of neurons immunoreactive for either 4-hydroxy-2-nonenal (c) or 3-nitrotyrosine (f) was counted in sections from mature (<10 years of age) and old (>16 years old) monkeys, and expressed as percent of the total number of neuromelanin-containing nigral neurons. Results are the means ± S.E.M.; **P < 0.005 versus the corresponding mature age group. Scale bar for panels a–e (in panel e) = 10 μm
Our present findings indicate that other mechanisms besides increased levels of unmodified \( \alpha \)-synuclein contribute to its phosphorylation and nitration. A number of kinases (e.g., casein kinases and G-protein-coupled receptor kinases) have been reported to partially phosphorylate \( \alpha \)-synuclein \textit{in vitro}. More recently, however, a primary role of PLK2 in catalyzing \( \alpha \)-synuclein phosphorylation at serine 129 has been underscored by evidence of its specific and quantitative (>95%) effect on \( \alpha \)-synuclein conversion.\(^5,20\) Furthermore, PLK2 levels have been reported to be enhanced in postmortem brains of patients affected by Alzheimer’s disease and Lewy body disease.\(^5\) In view of these considerations, we assessed a possible relationship between increased \( \alpha \)-synuclein phosphorylation and age-related PLK2 changes. Indeed, a significantly greater number of PLK2-immunoreactive dopaminergic cells characterized the substantia nigra of old monkeys. Double staining of midbrain tissue sections with antibodies against PLK2 and phospho-Ser 129 \( \alpha \)-synuclein revealed substantial colocalization in both adult and old monkeys. The number of colabeled neurons increased in older monkeys, further supporting a relationship between enhanced PLK2 expression and age-dependent \( \alpha \)-synuclein phosphorylation.
A pro-oxidant environment characterizes dopaminergic neurons and is reflected by their accumulation of neuromelanin, a product of dopamine oxidative metabolism. Evidence from earlier investigations suggests that, in the presence of neuromelanin and under oxidative conditions, α-synuclein may precipitate around pigment-associated lipid droplets. In this study, the effect of aging in promoting oxidative/nitrative reactions and α-synuclein/neuromelanin interactions was supported by findings showing (i) an increased number of neuromelanin-loaded cells with age, (ii) the occurrence of α-synuclein elevation almost exclusively within pigmented neurons and (iii) enhanced counts of neurons immunoreactive for 4-hydroxy-2-nonenal and 3-nitrotyrosine, two markers of oxidative/nitrative reactions. Taken together, these results are also compatible with the interpretation that α-synuclein accumulation in a setting favoring oxidative modifications leads to the formation of nitrated protein within aging dopaminergic cells.

Parallel increases in phosphorylated and nitrated α-synuclein raised the possibility that these modified forms of the protein may be generated within the same sub-population of nigral dopaminergic neurons. However, colocalization experiments did not support this hypothesis and, in the majority of instances, antibodies against phospho-Ser 129 and nitrated α-synuclein-labeled distinct neurons. This finding bears implications for the mechanisms of α-synuclein phosphorylation and nitration. If protein modifications were a mere consequence of enhanced α-synuclein, a greater degree of phospho-Ser 129 and nitrated α-synuclein colocalization might have been expected. Instead, limited immunostaining suggests that formation of phosphorylated and nitrated protein, although promoted by a common setting of age-related α-synuclein elevation, involves distinct mechanisms. As discussed above, older neurons with higher kinase expression would produce phospho-Ser 129 α-synuclein, whereas enhanced pro-oxidant conditions would favor the formation of nitrated protein.

Post-translational modifications affect the biological activity and toxic potential of α-synuclein. For example, phosphorylation has been suggested to modulate α-synuclein’s interaction with phospholipids and other proteins (e.g., tau), and nitrated α-synuclein is capable of inducing adaptive immune responses and may exacerbate microglial activation. Thus, neuronal α-synuclein accumulation and formation of phospho-Ser 129 and nitrated α-synuclein are age-related features of likely pathophysiological relevance. They could contribute to the progressive decline that characterizes the nigrostriatal system of older primates and have an important role in rendering aging dopaminergic cells increasingly vulnerable to neurodegenerative processes.

An important property of α-synuclein is its tendency to aggregate, which could underlie the pathogenesis of Lewy inclusions in PD and may cause neuronal injury via the formation of toxic oligomeric and fibrillar species. Several lines of experimental evidence indicate that phosphorylation and nitration are likely to affect α-synuclein aggregation, although the precise relationship linking protein modifications to aggregate formation remains unclear. Initial studies reported that phospho-Ser 129 α-synuclein promoted deposition of insoluble protein, whereas subsequent investigations showed opposite results. Similar inconsistencies have been found with nitrated α-synuclein, perhaps suggesting that the relationship between protein modifications and α-synuclein fibrillation/oligomerization may vary under different experimental conditions. Our present findings do not support a direct role of phospho-Ser 129 and/or nitrated α-synuclein in inducing aggregation. In fact, despite the substantial increase in unmodified, phosphorylated and nitrated protein, no overt evidence of insoluble α-synuclein was found in the substantia nigra of aged monkeys. It is possible that small (e.g., oligomeric) aggregates may be formed but remained undetected under our experimental conditions. An alternative interpretation, however, is that other factors in addition to age-related changes are necessary to trigger α-synuclein aggregation. Potential culprits include (i) α-synuclein mutations, (ii) destabilization of aggregation-resistant forms of the protein, (iii) impairment of neuronal mitochondrial function and (iv) toxic dopaminergic cell injury. All these conditions are capable of promoting aggregation and, on the background of normal aging, could enhance α-synuclein pathogenicity and ultimately have a role in neurodegenerative processes.
**Materials and Methods**

**Animals and tissue preparation.** A total of seven squirrel monkeys (*Saimiri sciureus*) of both sexes were obtained from Osage Research Primates (Osage Beach, MO, USA). The animals were individually housed in a room with a 13/11-h light/dark cycle, with free access to water and a daily diet of monkey chow and fresh fruit. Animals were divided into two different age groups: < 10 years of age (6–9 years, n = 4) and > 16 years old (17–19 years, n = 3). These two age groups, representing juvenile, adult and old animals, were chosen based on several observations in squirrel monkeys, including their average life span (18–22 years) and the age at which they reach sexual maturity and attain mature brain weight (2.5–3.5 years). All experimental protocols were in accordance with the standards established by the National Institutes of Health and the Office of the Prevention of Research Risks and were approved by the Institutional Animal Care and Use Committee.

The animals were euthanized using procedures consistent with the recommendations of the Panel of Euthanasia of the American Veterinary Medical Association. Animals were injected first with ketamine hydrochloride (15–20 mg/kg, i.m.) to provide restraint, and then with 0.22 ml/kg euthanasia solution (390 mg sodium pentobarbital and 50 mg phenytoin sodium/ml, i.v.). The brains were rapidly removed and dissected on ice. A tissue block encompassing the entire substantia nigra was fixed in 4% paraformaldehyde in 0.01 M phosphate-buffered saline (PBS, pH 7.4), cryoprotected in graded sucrose solutions and frozen in cold iso-pentane. Each midbrain block was cryostat-cut into 40-μm-thick sections through the full extent of the substantia nigra.

**Immunohistochemistry.** For bright-field microscopy, tissue sections were washed in PBS, and endogenous peroxidase was quenched by incubation in hydrogen peroxide solution. Sections were then blocked in 10% normal serum and washed in PBS, and endogenous peroxidase was quenched by incubation in hydrogen peroxide solution. Sections were then blocked in 10% normal serum and washed in PBS before incubation with hydrogen peroxide and primary antibodies. The substantia nigra was delineated at low magnification (× 1) using StereoInvestigator software (MBF Bioscience, Williston, VT, USA): the number of immunoreactive neurons was counted at higher magnification (× 100) using the software’s meander scan function. For each animal, values from the two sections were averaged. Data are presented as mean ± S.E.M. Differences among means were analyzed using one-way ANOVA. Newman–Keuls post hoc analysis was used when differences were observed in ANOVA testing (P < 0.05).

**Conflict of Interest**

The authors declare no conflict of interest.

**Acknowledgements.** This work is supported by grants from the Parkinson’s Disease Foundation and the Backus Foundation. We thank Drs. Amy Manning-Bog and Sarah Jewell for assistance with the experiments and manuscript review, and Dr. John P Anderson (Elan Pharmaceuticals, South San Francisco, California) for providing an antibody against phospho-Ser-129 α-synuclein.

---

**Table 2** List of antibodies used for bright-field and fluorescence microscopy

| Antigen                  | Supplier          | Species | Dilution |
|-------------------------|-------------------|---------|----------|
| Tyrosine hydroxylase    | Pel Freez         | Rabbit  | 1: 600   |
| α-Synuclein             | Millipore         | Mouse   | 1: 1000  |
| Phospho-Ser 129 α-synuclein | Wako  | Mouse  | 1:3000  |
| Phospho-Ser 129 α-synuclein | Gift  | Mouse  | 1:3000  |
| α-Synuclein:kinase 2    | Santa Cruz        | Rabbit  | 1: 100   |
| Nitrated α-synuclein    | Upstate           | Mouse   | 1: 3000  |
| 4-Hydroxy-2-nonenal     | Oxis Research     | Mouse   | 1: 300   |
| 3-Nitrotyrosine         | Upstate           | Rabbit  | 1: 100   |

*This antibody was generously provided by Elan Pharmaceuticals.

---

1. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goerdt M. Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998; 95: 6469–6473.
2. Tu PH, Galvin JE, Babu M, Glasson B, Tomita T, Leight S et al. Glial cytoplasmic inclusions in the substantia nigra are present in some neurodegenerative diseases and may be absent in others. Acta Neuropathol 1999; 97: 585–591.
3. Baik H, Del Tredici K, Rub U, de Voos RA, Jansen Steur EN, Braak E. Staging of brain amyloidosis in Alzheimer’s disease: a postmortem neuropathological study. Acta Neuropathol 2001; 101: 415–422.
4. Dauer WT, Wienecke RA. A transgenic mouse model of Parkinson’s disease. Trends Neurosci 2000; 23: 197–202.
5. Glasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI et al. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 2002; 298: 985–989.
6. Hodara R, Norris EH, Glasson BI, Mihatschen-Eberz AJ, Lynch DR, Lee VM et al. Functional consequences of α-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem 2004; 279: 47748–47753.
7. Paleologou KE, Boucharab A, Oueuil A, Schell H, Fournier M et al. Phosphorylation of synucleins by members of the polo-like kinase family. J Biol Chem 2010; 285: 2807–2822.
8. Glasson BI, Duda JE, Murray IV, Chen Q, Souza-JM, Hurtig HI et al. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 2002; 298: 985–989.
13. Li W, Lesuisse C, Xu Y, Troncoso JC, Price DL, Lee MK. Stabilization of α-synuclein protein with aging and familial Parkinson’s disease-linked A53T mutation. J Neurosci 2004; 24: 7400–7409.

14. Chu Y, Kordower JH. Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson’s disease? Neurobiol Dis 2007; 28: 134–149.

15. Xuan Q, Xu SL, Lu DH, Yu S, Zhou M, Ueda K et al. Increase expression of α-synuclein in aged human brain associated with neurodegeneration. J Neurotransm 2011; 118: 1575–1583.

16. Mak SK, McCormack AL, Langston JW, Kordower JH, Di Monte DA. Decreased α-synuclein expression in the aging mouse substantia nigra. Exp Neurol 2009; 220: 359–365.

17. Anderson JP, Walker DE, Goldstein JM, de Laat R, Balducci K, Caccavello RJ et al. Superiority of PLK-2 as a-synuclein phosphorylating agent relies on unique specificity determinants. Biochem Biophys Res Commun 2012; 418: 156–160.

18. Cuervo AM, Stefani L, Frederburg R, Laneyburg PT, Sulzer D. Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy. Science 2004; 305: 1292–1295.

19. Martinez-Vicente M, Tallozcy Z, Kauhisk S, Cuervo AM. Chaperone-mediated autophagy. Methods Mol Biol 2008; 445: 227–244.

20. Salvi M, Trash E, Marin O, Negro A, Samo S, Pinna LA. Superiority of PLK-2 as α-synuclein phosphorylating agent relies on unique specificity determinants. Biochem Biophys Res Commun 2012; 418: 156–160.

21. Cuervo AM, Stefani L, Frederburg R, Laneyburg PT, Sulzer D. Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy. Science 2004; 305: 1292–1295.

22. Kaushik S, Cuervo AM. Chaperone-mediated autophagy. Methods Mol Biol 2008; 445: 227–244.

23. Martinez-Vicente M, Tallozcy Z, Kauhisk S, Massey AC, Mazzulli J, Mosharov EV et al. Dopamine-modified α-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008; 118: 777–788.

24. Gram DG. Oxidative pathways for catecholamines in the genesis of neurodegeneration and cytotoxic quinones. Mol Pharmacol 1978; 14: 633–643.

25. Fasano M, Ophth A, Broe M, Jensen PH, Kettle E, Fedorow H et al. α-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson’s disease. Brain 2005; 128: 2654–2664.

27. Pronin AN, Morris AJ. Surguchov, Benovic JL. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J Biol Chem 2000; 275: 26515–26522.

28. Berrier EJ, Banerjee R, Reynolds AD, Sherman S, Pisaev VM, Taliperson V et al. Nitration α-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 2009; 4: e1376.

29. Reynolds AD, Stone DK, Moisley RL, Gendelman HE. Nitration α-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol 2009; 182: 4137–4149.

30. McCormack AL, Di Monte DA, Delfani K, Irwin I, DeLaaney LE, Langston WJ et al. Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol 2004; 471: 387–395.

31. Yamim G, Uversky VN, Fink AL. Nitration inhibits fibrillation of human α-synuclein in vitro by formation of soluble oligomers. FEBS Lett 2002; 542: 147–152.

32. Li J, Uversky VN, Fink AL. Effect of familial Parkinson’s disease point mutations A30P and A35T on the structural properties, aggregation, and fibrillation of human α-synuclein. Biochemistry 2001; 40: 11604–11613.

33. Marteles T, Choi GJ, Sekine DJ. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011; 477: 110–115.

34. Lee HJ, Shin SY, Choi C, Lee YH, Lee SJ. Formation and removal of α-synuclein aggregates in cell exposed to mitochondrial inhibitors. J Biol Chem 2002; 277: 5411–5417.

35. McCormack AL, Mak SK, Shenasa M, Langston WJ, Forno LS, Di Monte DA. Pathologic modifications of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. J Neuropathol Exp Neurol 2003; 62: 502–509.

36. Kanaan NM, Kordower JH, Collier TJ. Age-related accumulation of Marinesco bodies and α-synuclein expression in the aging mouse substantia nigra. J Comp Neurol 2009; 515: 134–149.

37. Pronin AN, Morris AJ. Surguchov, Benovic JL. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J Biol Chem 2000; 275: 26515–26522.

38. Berrier EJ, Banerjee R, Reynolds AD, Sherman S, Pisaev VM, Taliperson V et al. Nitration α-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 2009; 4: e1376.

39. Reynolds AD, Stone DK, Moisley RL, Gendelman HE. Nitration α-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol 2009; 182: 4137–4149.

40. McCormack AL, Di Monte DA, Delfani K, Irwin I, DeLaaney LE, Langston WJ et al. Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol 2004; 471: 387–395.